Editas Medicine Set to Present at the ESGCT Annual Congress
Editas Medicine's Upcoming Presentation Highlights
Editas Medicine, Inc. (NASDAQ: EDIT), a trailblazer in gene editing, is excited to announce that it will present at the renowned European Society of Gene and Cell Therapy (ESGCT) Congress. The congress is set to occur from October 7 to October 10, making this a significant occasion for the company and the field of gene therapy.
About the ESGCT Congress
The ESGCT Congress provides a vibrant platform for discussing the latest advancements in gene therapy and cell therapy, drawing experts from around the globe to exchange knowledge and collaborate on future strategies. Editas Medicine will present groundbreaking findings related to its innovative CRISPR gene editing technology during this major conference.
Details of the Presentation
During the congress, one of the highlights will be an oral presentation titled "A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates." This significant research finding will be presented by Linda Burkly, Ph.D., who serves as the Executive Vice President and Chief Scientific Officer at Editas Medicine.
Session Information
The presentation is scheduled for October 9 at 5:00 p.m. CEST (11:00 a.m. ET) as part of the session focused on gene editing applications. Dr. Burkly’s research, documented in Final Abstract Number OR069, showcases the potential of gene editing as a therapeutic tool to transform healthcare.
Availability of Abstracts
For attendees and interested parties, the abstracts from the congress will be available on the ESGCT website, offering insights into the latest research presented at the event. Furthermore, for those who cannot attend, Editas Medicine will later share the presentation material on their website in the "Posters & Presentations" section.
Participation in Investor Conferences
In addition to its participation at ESGCT, Editas Medicine is set to engage in several investor conferences throughout October. These include:
- H.C. Wainwright Genetic Medicines Virtual Conference
Format: Fireside Chat
Date: Tuesday, October 14
Location: Virtual - Chardan 9th Annual Genetic Medicines Conference
Panel Discussion: Genome Editing: Next Wave Technologies
Date: Tuesday, October 21, 8:45 a.m. ET
Location: New York, NY
Access to Presentations
Investors and stakeholders can access live webcasts of these crucial presentations through the "Investors" section of Editas Medicine's website. An archived replay will also be available for approximately 30 days following each event, allowing broader access to those interested in the company’s advancements.
About Editas Medicine
Editas Medicine stands at the forefront of revolutionizing the treatment of serious diseases through its pioneering gene editing capabilities. The company aims to bring transformative in vivo medicines enabled by CRISPR technology to patients worldwide. With a focus on developing, producing, and commercializing durable gene editing solutions, Editas Medicine continues to lead in the commercialization of gene editing therapies.
Stay Updated with Editas Medicine
For the latest news and scientific advancements, individuals are encouraged to visit Editas Medicine's official website. The company frequently shares updates regarding new research findings, partnerships, and events.
Frequently Asked Questions
What is the focus of Editas Medicine?
Editas Medicine focuses on developing transformative gene editing therapies using CRISPR technology to treat serious diseases.
When will the ESGCT Congress take place?
The ESGCT Congress is scheduled from October 7 to October 10.
Who will present at the congress for Editas Medicine?
Linda Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, will present at the congress.
How can I access the presentations from the conference?
Presentations will be available on Editas Medicine's website in the "Posters & Presentations" section after the event.
What upcoming events will Editas Medicine participate in?
Editas Medicine will participate in the H.C. Wainwright Genetic Medicines Virtual Conference and the Chardan 9th Annual Genetic Medicines Conference in October.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.